Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00303797 · ClinicalTrials.gov registry record · Phase 1

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Refractory Multiple Myeloma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT00303797 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Refractory Multiple Myeloma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00303797, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Refractory Multiple Myeloma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This phase I trial is studying the side effects and best dose of sorafenib and bortezomib in treating patients with advanced cancer. Sorafenib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of cancer cells by blocking blood flow to the cancer

Conditions Studied

Unspecified Adult Solid Tumor, Protocol Specific Refractory Multiple Myeloma Refractory Chronic Lymphocytic Leukemia Stage III Multiple Myeloma Stage IV Chronic Lymphocytic Leukemia

Interventions

  • DRUG sorafenib tosylate
  • DRUG 17-N-allylamino-17-demethoxygeldanamycin/bortezomib

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2005-12
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00303797

The ClinicalTrials.gov registry entry for NCT00303797 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (90% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which sorafenib tosylate is the first listed.

NCT00303797 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT00303797 about?

NCT00303797 is a clinical study titled "Sorafenib and Bortezomib in Treating Patients With Advanced Cancer". This phase I trial is studying the side effects and best dose of sorafenib and bortezomib in treating patients with advanced cancer. Sorafenib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of cancer cells...

What is the current status of trial NCT00303797?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2005-12.

What conditions does trial NCT00303797 study?

This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Refractory Multiple Myeloma, Refractory Chronic Lymphocytic Leukemia, Stage III Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia.

What interventions are being tested in trial NCT00303797?

The interventions under investigation include: sorafenib tosylate (DRUG), 17-N-allylamino-17-demethoxygeldanamycin/bortezomib (DRUG).

Who is sponsoring clinical trial NCT00303797?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00303797 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Unspecified Adult Solid Tumor, Protocol Specific

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Unspecified Adult Solid Tumor, Protocol Specific

All registered trials for this condition

Refractory Multiple Myeloma

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.